Novo Nordisk’s Stock Surge: A Cosmic Weight-Loss Odyssey
The market’s enthusiasm was, to be fair, somewhat understandable. One announcement detailed a potential successor to Wegovy, the drug that’s turned obesity into a lucrative niche for the company. The other suggested that Wegovy might do more than just melt away pounds-it might also help people stop thinking about cake. (A development so profound it could rival the invention of the tea bag.)